Business
Bionano Genomics Announces Publication of the First Study to Combine OGM and NGS to Evaluate Myeloid Cancers
Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panelFirst study to publish results using NxClinical software for simultaneous visualization and interpretation of sequence and copy number variants from NGS and OGM data SAN DIEGO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data today announced the publication of a study that evaluated the performance and clinical utility of combining OGM and a 523-gene next-generation sequencing (NGS) panel for comprehensive evaluation of myeloid tumors and compared it to standard cytogenetic methods (karyotyping and fluorescence in situ hybridization (FISH) and a 54-gene NGS panel. This study reported superior performance as compared to standard methods and marks two major developments in the ongoing evaluation of combined OGM and NGS workflows. This study is the first published example where the combination of workflows was applied in the context of myeloid cancers, and demonstrated higher sensitivity, resolution, accuracy and ability to reveal cryptic and clinically relevant novel variants in myeloid cancers as compared to standard methods. This is also the first study to publish results using the simultaneous visualization and interpretation of sequence and copy number variants (CNVs) in the BioDiscovery NxClinical software v6.1 from OGM and NGS data. “This research demonstrated that the combination of OGM and a 523-gene NGS panel is superior to standard methods and cost effective for comprehensive genomic profiling of myeloid cancers. When compared to whole-genome sequencing approaches that others have suggested, I believe it has better detection performance at a lower cost,” commented Dr. Ravindra Kolhe, Associate Dean for Translational Research at Medical College of Georgia and Director of the Georgia Esoteric and Molecular Laboratory at Augusta University. “With new tools to simultaneously visualize sequence variants and structural variants, we are well-positioned to move this approach into routine use, which we expect will deepen our understanding of hematologi...